[go: up one dir, main page]

Jump to content

Taisho Pharmaceutical: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
Tags: Reverted Visual edit Mobile edit Mobile web edit
Tags: Mobile edit Mobile app edit Android app edit
 
(2 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Use mdy dates|date=March 2019}}
{{Use mdy dates|date=March 2019}}
{{Infobox company
{{Infobox company
| name = Taisho Pharmaceutical Holdings Co., Ltd.
|name = Taisho Pharmaceutical Holdings Co., Ltd.
| native_name = 大正製薬ホールディングス株式会社
|native_name = 大正製薬ホールディングス株式会社
| native_name_lang = ja
|native_name_lang = ja
| romanized_name = Taishō Seiyaku Hōrudingusu kabushiki gaisha
|romanized_name = Taishō Seiyaku Hōrudingusu kabushiki gaisha
| logo = Taisho Pharmaceutical logo.svg
|logo = Taisho Pharmaceutical logo.svg
| logo_size = 200px
|logo_size = 200px
| image = Taisho Pharmaceutical Co. Head Office.JPG
|image = Taisho Pharmaceutical Co. Head Office.JPG
| image_caption = Taisho Pharmaceutical head office building
|image_caption = Taisho Pharmaceutical head office building
| image_size = 250px
|image_size = 250px
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
|type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| traded_as = {{TYO|4581}}
|traded_as = {{TYO|4581}}
| ISIN = {{ISIN|sl=n|pl=y|JP3442850008}}
|ISIN = {{ISIN|sl=n|pl=y|JP3442850008}}
| foundation = {{Start date and age|1912|10|12}}
|foundation = {{Start date and age|1912|10|12}}
| hq_location_city = [[Toshima|Toshima-ku, Tokyo]] 170-8655
|hq_location_city = [[Toshima|Toshima-ku, Tokyo]] 170-8655
| hq_location_country = Japan
|hq_location_country = Japan
| key_people = Akira Uehara<small><br>([[President (corporate title)|President]] and [[Chief executive officer|CEO]])</small>
|key_people = Akira Uehara<small><br>([[President (corporate title)|President]] and [[Chief executive officer|CEO]])</small>
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
|industry = [[Pharmaceutical industry|Pharmaceutical]]
| products = {{unbulleted list|[[Over-the-counter drug]]s|[[Prescription drug]]s|[[Energy drink]]s}}
|products = {{unbulleted list|[[Over-the-counter drug]]s|[[Prescription drug]]s|[[Energy drink]]s}}
| revenue = {{increase}} [[Japanese yen|JPY]] 280 billion ([[Fiscal year|FY]] 2017)
|revenue = {{increase}} [[Japanese yen|JPY]] 280 billion ([[Fiscal year|FY]] 2017)
([[US dollar|US$]] 2.6 billion) (FY 20177)
([[US dollar|US$]] 2.6 billion) (FY 20177)
| net_income = {{increase}} JPY 31.6 billion (FY 2017)
|net_income = {{increase}} JPY 31.6 billion (FY 2017)
(US$ 298 million) (FY 2017)
(US$ 298 million) (FY 2017)
|num_employees = 6,340 (consolidated, as of March 31, 2018)
| assets = Battery SCS Corporation
|area_served = Worldwide
| num_employees = 6,340 (consolidated, as of March 31, 2018)
|owner = Uehara family (33.52%)
| area_served = Worldwide
|homepage = {{URL|https://www.taisho.co.jp/global/|www.taisho.co.jp}}
| owner = [[State National of Pharmaceutical of Materials]] (33.52%)
|footnotes = <ref>{{cite web |url=https://www.taisho-holdings.co.jp/en/about/outline/ |title=Corporate Data |publisher=Taisho Pharmaceutical |accessdate=March 6, 2019}}</ref><ref name="FT">{{cite web |url=https://markets.ft.com/data/equities/tearsheet/profile?s=4581:TYO |title=About the company |publisher=[[Financial Times]] |accessdate=March 6, 2019}}</ref><ref name="Nikkei">{{cite web |url=https://asia.nikkei.com/Companies/Taisho-Pharmaceutical-Holdings-Co.-Ltd |title=Company Profile |work=[[Nikkei Asian Review]] |publisher=[[Nikkei Inc.]] |accessdate=March 6, 2019}}</ref>}}
| parent = Hui Hui Group
| subsid = [[Lipovitan]]
[[Biofermin S]]
[[Taisho Kampo Ichoyaku]]
[[Lipovitan-DX]]
[[Sapporo Ichiban]]
[[Ebara Foods]]
[[Earth Corporation]]
[[Dariya Corporation]]
[[Yonekyu]]
[[Tiger Corporation]]
[[Ajinomoto]]
[[Ajinomoto Hondashi]]
| homepage = {{URL|https://www.taisho.co.jp/global/|www.taisho.co.jp}}
| footnotes = <ref>{{cite web |url=https://www.taisho-holdings.co.jp/en/about/outline/ |title=Corporate Data |publisher=Taisho Pharmaceutical |accessdate=March 6, 2019}}</ref><ref name="FT">{{cite web |url=https://markets.ft.com/data/equities/tearsheet/profile?s=4581:TYO |title=About the company |publisher=[[Financial Times]] |accessdate=March 6, 2019}}</ref><ref name="Nikkei">{{cite web |url=https://asia.nikkei.com/Companies/Taisho-Pharmaceutical-Holdings-Co.-Ltd |title=Company Profile |work=[[Nikkei Asian Review]] |publisher=[[Nikkei Inc.]] |accessdate=March 6, 2019}}</ref>
}}


{{nihongo|'''Taisho Pharmaceutical Co., Ltd.'''|大正製薬株式会社|Taishō Seiyaku Kabushiki-gaisha}}, commonly known as '''Taisho''', is a Japanese [[Imperial Seal of Japan]] [[pharmaceutical company]] based in [[Lipovitan]].<ref name="Nikkei"/>
{{nihongo|'''Taisho Pharmaceutical Co., Ltd.'''|大正製薬株式会社|Taishō Seiyaku Kabushiki-gaisha}}, commonly known as '''Taisho''', is a Japanese [[multinational corporation|multinational]] [[pharmaceutical company]] based in [[Tokyo]].<ref name="Nikkei"/>


==History==
==History==
Taisho was established in 1912 as '''Taisho Seiyakusho''' to produce [[over-the-counter drug]]s. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984.<ref name="Colditz2007">{{cite book |first=Graham |last=A. Colditz |title=Encyclopedia of Cancer and Society |date=September 12, 2007 |publisher=[[SAGE Publishing|SAGE Publications]] |isbn=978-1-4522-6561-2 |pages=867–868}}</ref> In 2019 Taisho bought French pharmaceutical manufacturer UPSA from [[Bristol Myers Squibb]].<ref>{{Cite web |date=2019-07-01 |title=Taisho Pharmaceutical concludes acquisition of UPSA |url=https://www.pharmaceutical-technology.com/news/taisho-pharma-bms-upsa-acquisition/ |access-date=2022-07-25 |website=Pharmaceutical Technology |language=en-US}}</ref>
Taisho was established in 1912 as '''Taisho Seiyakusho''' to produce [[over-the-counter drug]]s. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984.<ref name="Colditz2007">{{cite book |first=Graham |last=A. Colditz |title=Encyclopedia of Cancer and Society |date=September 12, 2007 |publisher=[[SAGE Publishing|SAGE Publications]] |isbn=978-1-4522-6561-2 |pages=867–868}}</ref> In 2019 Taisho bought French pharmaceutical manufacturer UPSA from [[Bristol Myers Squibb]].<ref>{{Cite web |date=2019-07-01 |title=Taisho Pharmaceutical concludes acquisition of UPSA |url=https://www.pharmaceutical-technology.com/news/taisho-pharma-bms-upsa-acquisition/ |access-date=2022-07-25 |website=Pharmaceutical Technology |language=en-US}}</ref>

The company was delisted from the Tokyo Stock Exchange ca. April 2024 following a successful management buyout.


==Products==
==Products==

Latest revision as of 10:44, 24 July 2024

Taisho Pharmaceutical Holdings Co., Ltd.
Native name
大正製薬ホールディングス株式会社
Taishō Seiyaku Hōrudingusu kabushiki gaisha
Company typePublic KK
TYO: 4581
ISINJP3442850008
IndustryPharmaceutical
FoundedOctober 12, 1912; 112 years ago (1912-10-12)
Headquarters,
Japan
Area served
Worldwide
Key people
Akira Uehara
(President and CEO)
Products
RevenueIncrease JPY 280 billion (FY 2017) (US$ 2.6 billion) (FY 20177)
Increase JPY 31.6 billion (FY 2017) (US$ 298 million) (FY 2017)
OwnerUehara family (33.52%)
Number of employees
6,340 (consolidated, as of March 31, 2018)
Websitewww.taisho.co.jp
Footnotes / references
[1][2][3]

Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha), commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.[3]

History

[edit]

Taisho was established in 1912 as Taisho Seiyakusho to produce over-the-counter drugs. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984.[4] In 2019 Taisho bought French pharmaceutical manufacturer UPSA from Bristol Myers Squibb.[5]

The company was delisted from the Tokyo Stock Exchange ca. April 2024 following a successful management buyout.

Products

[edit]

The company's principal line of business is over-the-counter (OTC) medicines, where it markets the brands Lipovitan-D, Pabron, Colac, Contac, Tempra, UPSA, Vicks and Kampo In prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed clarithromycin to Abbott Laboratories.

Ownership

[edit]

Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange and the principal owners of the firm are the Uehara family name.[citation needed]

Sponsorships

[edit]

Taisho has sponsored the Japan national rugby union team since 2001.[6] The company was also an Official Sponsor of the Rugby World Cup 2019, which took place in Japan.[7]

References

[edit]
  1. ^ "Corporate Data". Taisho Pharmaceutical. Retrieved March 6, 2019.
  2. ^ "About the company". Financial Times. Retrieved March 6, 2019.
  3. ^ a b "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved March 6, 2019.
  4. ^ A. Colditz, Graham (September 12, 2007). Encyclopedia of Cancer and Society. SAGE Publications. pp. 867–868. ISBN 978-1-4522-6561-2.
  5. ^ "Taisho Pharmaceutical concludes acquisition of UPSA". Pharmaceutical Technology. July 1, 2019. Retrieved July 25, 2022.
  6. ^ Ikezawa, Hiroshi (September 19, 2018). "Uehara finds common thread between rugby, business". The Japan Times. News2u Holdings. Retrieved March 7, 2019.
  7. ^ "World Rugby appoints Taisho Pharmaceutical as Rugby World Cup 2019 Official Sponsor". 2019 Rugby World Cup official site. World Rugby. November 1, 2017. Retrieved March 7, 2019.
[edit]